The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Investors recently learned about undisclosed data from one of Amgen's clinical trials ... a loss of bone density. Such a loss ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Both stocks were also bolstered by a major setback for a competing weight-loss shot being developed by Amgen Inc. Trump’s ...

Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...